Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1701 + albumin paclitaxel
- Development stage
- Unknown
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SHR-1701 + albumin paclitaxel is a combination therapy used in oncology, currently under investigation primarily for pancreatic cancer. SHR-1701 is a bifunctional fusion protein composed of a monoclonal antibody against programmed death ligand 1 (PD-L1) fused to the extracellular domain of transforming growth factor-beta (TGF-β) receptor II, enabling simultaneous PD-L1 blockade and TGF-β sequestration. Albumin paclitaxel (nab-paclitaxel, Abraxane) is a solvent-free, albumin-bound formulation of the taxane chemotherapeutic paclitaxel, allowing for enhanced tumor delivery through albumin receptor-mediated transcytosis, improved pharmacokinetics, and reduced hypersensitivity reactions. The combination regimen is being clinically evaluated in untreated locally advanced or metastatic pancreatic adenocarcinoma, where SHR-1701 provides dual immune checkpoint and TGF-β pathway inhibition, and albumin paclitaxel arrests tumor cell division by stabilizing microtubules and blocking mitosis[3][6][2][5][8].
- Other names
- protein-bound paclitaxelnanoparticle paclitaxelpaclitaxel albumin-stabilized nanoparticle formulation
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB3 (Transforming growth factor beta 3)TUBB (Tubulin (alpha and beta subunits))TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on SHR-1701 + albumin paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1701 + albumin paclitaxel.